Zydus Lifesciences' Dasatinib Tablets Get USFDA Approval, To Manufacture At Ahmedabad Unit
Zydus Lifesciences Ltd. on Wednesday announced receiving approval from the United States Food and Drug Administration for the Dasatinib tablets.
The pharmaceutical company, along with its subsidiaries and affiliates, has received final approval from the USFDA to manufacture Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, according to its exchange filing.
The Dasatinib tablets—which are used for treating chronic myeloid leukaemia in newly diagnosed adults—will be manufactured at Zydus Lifesciences' unit in its special economic zone located in Ahmedabad.
The medication can also be used to treat adults with chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.
Those with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy can also use it.
According to analytics platform IQVIA MAT, the annual sales of Dasatinib tablets stood at $1,807.7 million in the United States for the month of January 2025.
The group now has 415 approvals and has, as of Dec. 31, 2024, filed 483 ANDAs since the commencement of the filing process in FY 2003-04, the company added.
In the third quarter of FY2024-25, Zydus Lifesciences' consolidated net profit rose nearly 30% to Rs 1,024 crore.
The company had reported that income from its US formulations business has grown 31% to Rs 2,409.6 crore during the period.
Revenue in the quarter under review rose 17% to Rs 5,269 crore against Rs 4,505 crore in the similar period of last fiscal.
Shares of Zydus Lifesciences Ltd. closed 1.85% higher at Rs 887.95 apiece on the BSE, compared to a 1.01% advance in the benchmark Sensex.
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
